Alzinova Ab · OMXSTO:ALZ
Alzinova Ab — Investor Presentation (October 2022)
28 slides from Alzinova Ab's investor presentation, October 2022
Slide 1: We will make it possible for Alzheimer's patients to live an independent and active life
We will make it possible for Alzheimer's patients to live an independent and active life Company presentation October 2022
Slide 2: Forward looking statements
Forward looking statements This information contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strate
Slide 3: Alzinova is developing the first specific vaccine against Alzheimer's disease
Alzinova is developing the first specific vaccine against Alzheimer’s disease Swedish biopharma company Based in Gothenburg. Founded 2011 High unmet medical need for Alzheimer’s disease – huge market opportunity Innovative science and proprietary technology enables development of disease-modifying t
Slide 4: Every 5 seconds someone is affected by Alzheimer's disease
Every 5 seconds someone is affected by Alzheimer’s disease 4 ©2022 Alzinova AB (publ), All rights reserved
Slide 5: Alzheimer's disease
Alzheimer’s disease • Slowly progressing disease • Symptoms such as memory loss, confusion, apathy, dizziness, difficulties solving simple tasks etc. • Caused by toxic formations in the brain called oligomers – consists of Aβ-42 peptide • Destroys the brain structures • Need for targeted treatment t
Slide 6: Alzheimer's disease is a progressively debilitating disease - huge unmet medical need
Alzheimer’s disease is a progressively debilitating disease - huge unmet medical need Dementia >55 million people suffer from dementia Impacts quality of life US $1.3 trillion >150 million people in 2050 (US $2.8 trillion by 2030) Patients, Annual cost families, care givers 60-70% is Alzheimers pati
Slide 7: >100 million people will suffer from Alzheimer's in 2050
>100 million people will suffer from Alzheimer’s in 2050 7 ©2022 Alzinova AB (publ), All rights reserved
Slide 8: Enormous market potential. Blockbuster status predicted for Alzheimer's treatments by 2026
Enormous market potential. “Blockbuster status” predicted for Alzheimer’s treatments by 2026 Alzheimer’s therapeutics market = US $13 billion by 2028 Sales and revenue potential of a new drug is substantial Substantial market Two of 7 predicted blockbusters by 2026 are new anti-Alzheimer’s drugs pot
Slide 9: Imagine if there was a vaccine against Alzheimer's disease
Imagine if there was a vaccine against Alzheimer's disease 9 ©2022 Alzinova AB (publ), All rights reserved
Slide 10: Two differentiated, oligomer-specific products based on the same proprietary technology
Two differentiated, oligomer- specific products based on the same proprietary technology • Highly specific disease modifying treatments, directed towards the toxic accumulations of amyloid beta in the brain • Opportunity to become effective and well tolerated treatments to halt and prevent Alzheimer
Slide 11: AβCC peptide technology enables high precision, targeting the toxic oligomers
Alzinova’s AβCC peptide™ technology enables high precision, with antibodies specifically targeting the toxic oligomers Aβ – amyloid-beta 11 ©2022 Alzinova AB (publ), All rights reserved
Slide 12: ALZ-101 and ALZ-201 represent a potential breakthrough in treating Alzheimer's Disease
ALZ-101 and ALZ-201 represent a potential breakthrough in treating Alzheimer's Disease ALZ-101 vaccine ALZ-201 monoclonal antibody • The body generates antibodies against toxic • Unique binding profile for targeting oligomers oligomers in brain • Several potential uses for the antibody: • High patie
Slide 13: Alzinova's product pipeline offers complementary ways to fight Alzheimer's Disease
Alzinova's product pipeline offers complementary ways to fight Alzheimer’s Disease Candidates Discovery Pre-clinical Clinical NDA/MAA Next Major Milestone ALZ-1011) therapeutic >50% recruited in H2 2023 Topline data vaccine phase 1b study clinical phase 1b ALZ-2012) monoclonal antibody TBD “Phase 1
Slide 14: Alzinova's unique position for treating Alzheimer's
Alzinova’s unique position for treating Alzheimer’s Alzinova Other actors Targeted treatment that specifically neutralizes the Target plaques, which are toxic peptides that are central to the development of believed to contain both toxic Alzheimer’s disease and harmless protein. Vaccine stimulates t
Slide 15: Strong data supports clinical development of ALZ-101
Strong data supports clinical development of ALZ-101 • Comprehensive pre-clinical results – ALZ-101 is well tolerated in non-clinical safety and toxicity studies (monkeys and rabbits) ✓ – Efficacy data in three different Alzheimer’s models, all showing promising results ✓ – Transgenic mice, – Aβ-imm
Slide 16: ALZ-101 Phase 1b clinical study in patients with Alzheimer's disease
ALZ-101 Phase 1b clinical study in patients with Alzheimer’s disease Study: Double-blind, randomized, placebo-controlled study on safety, tolerability and immunogenicity. 20-week study with ALZ-101 (125 and 250 μg) or placebo, given at weeks 0, 4, 8 and 16 with a follow-up period of 48 weeks. Patien
Slide 17: Phase 2 preparations
Phase 2 preparations • Study extension of phase 1b – Possibility for existing patients to continue – Long-term data for safety & tolerability – Biomarker data – Cognitive data – Advantages ahead of Phase 2 • Comprehensive preparation work – Prepared & validated scalable manufacturing process – Fast
Slide 18: Development of ALZ-101 & ALZ-201 - Strategic plan ahead
Development of vaccine ALZ-101 & monoclonal antibody ALZ-201 - Strategic plan ahead ALZ-101 vaccine - phase 1b study ALZ-201 monoclonal antibody – phase 1 ready • 1 year recruitment – ongoing • Development and scale up of manufacturing of • Recommendation from independent expert group monoclonal ant
Slide 19: ALZ-101 and ALZ-201 are patented through two patent families
ALZ-101 and ALZ-201 are patented through two patent families Stable amyloid-beta monomers and oligomers (ALZ-101) Region/Country Patent number Status Expiry date Australia 2009236699 Granted 2029-04-14 Active patent strategy Europe(1) 2262526 Granted 2029-04-14 Japan 5817060 Granted 2029-04-14 Japan
Slide 20: Roadmap & value inflection points
Roadmap & value inflection points ALZ-101 Pre-clinical phase ALZ-101 Scaled up production Phase 1b study fully recruited ALZ-101 Phase 1b study results ALZ-201 Phase 1b Study 2015 2022 Q2 2022 Q4 2023 Q3- Q4 2024+ 2020 2021 2022 Q2/Q3 2023 2023+ 2024+ ALZ-201 ALZ-101 Phase 1b study Phase 1b safety r
Slide 21: Alzinova's business model: develop, document, prepare, partner & bring to market
Alzinova's business model: develop, document, prepare, partner & bring to market Develop breakthrough disease-modifying treatments based on proprietary AβCC technology Document safety and tolerability in patients with Alzheimer’s disease Prepare (in parallel) for phase 2 to optimize the candidates v
Slide 22: Experienced management team and innovation-focused collaborations
Experienced management team and innovation- focused collaborations Kristina Torfgård, PhD Anders Sandberg, PhD Anders Bylock, MD, PhD Chief Executive Officer Chief Scientific Officer and Chief Medical Officer 30 years experience from leading Co-Founder >30 years experience in drug roles in pharma an
Slide 23: Board of Directors with extensive pharma and biopharma experience
Board of Directors with extensive pharma and biopharma experience Björn Larsson Anders Blom Per-Göran Gillberg, PhD Chairman >25 years experience in inter- 35 years experience in drug >25 years experience in marketing, national finance and business development in pharma and biopharma sales and busin
Slide 24: Capitalization table, summary of shares and options
Capitalization table, summary of shares and options Shareholders, as per 10 August 2022: Name No. of shares Capital, % Maida Vale Capital AB 5 515 314 17,01% Market cap Försäkrings AB Avanza Pension 2 722 727 8,40% ~100 Share options Mangold Fondkommission AB 1 861 424 5,74% MSEK 2020/2023 Nordnet P
Slide 25: Financial information - Key figures, for Q1-Q2 2022
Financial information - Key figures, for Q1-Q2 2022 Total balance Cash Equity Cashflow Result sheet balance ratio 117 44 15,2 -11 234 96,5% (99) (41) (-14,9) (-0 000) (93,7%) MSEK MSEK MSEK MSEK • Mainly invested in capitalized costs for R&D, focus on preparing ALZ-101 for phase 2 studies • Rights i
Slide 26: Alzinova can reach a potential breakthrough for treatment of Alzheimer's
Alzinova can reach a potential breakthrough for treatment of Alzheimer’s High unmet medical & market potential for disease-modifying treatments of Alzheimer’s disease ✓ Short-term goal: ✓ Mid-term goal: ✓ Long-term goal: • First clinical trial targeting oligomers with a • ALZ-101 “Phase 2 ready” H2
Slide 27: Investment highlights
Investment highlights Alzinova’s goal is to enable Alzheimer’s patients to live an independent and active life. Alzinova’s lead candidate, ALZ-101, is a therapeutic vaccine against Alzheimer’s disease. The vaccine is in clinical development with a phase 1b study in Alzheimer’s patients. Based on the
Slide 28: We will make it possible for Alzheimer's patients to live an independent and active life
We will make it possible for Alzheimer's patients to live an independent and active life For further information, please contact: CEO Kristina Torfgård Email: kristina.torfgard@alzinova.com Phone: +46 70 846 79 75 www.alzinova.com https://www.linkedin.com/company/alzinova-ab/ ©2022 Alzinova AB (publ